NCT05419479 2026-02-24
Switch Maintenance in Pancreatic
Dana-Farber Cancer Institute
Phase 1/2 Suspended
Clinical Trials
12 trialsNCT02600949 2026-01-29
Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT04130854 2026-01-28
INNATE: Immunotherapy During Neoadjuvant Therapy for Rectal Cancer
University of Texas Southwestern Medical Center
Phase 2 Active not recruiting
NCT02706353 2025-11-21
APX005M in Combination With Systemic Pembrolizumab in Patients With Metastatic Melanoma
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT04495257 2025-10-30
A Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell Carcinoma (RCC)
Yale University
Phase 1 Active not recruiting
NCT03719430 2025-04-29
APX005M and Doxorubicin in Advanced Sarcoma
Columbia University
Phase 2 Active not recruiting
NCT03502330 2024-07-03
APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma
Yale University
Phase 1 Completed
NCT04337931 2024-02-13
A Study to Evaluate Sotigalimab (APX005M) in Subjects With Unresectable or Metastatic Melanoma
Apexigen America, Inc.
Phase 2 Terminated
NCT03123783 2023-12-26
CD40 Agonistic Antibody APX005M (Sotigalimab) in Combination With Nivolumab
Apexigen America, Inc.
Phase 1/2 Completed
NCT02482168 2023-12-20
Study of the CD40 Agonistic Monoclonal Antibody APX005M
Apexigen America, Inc.
Phase 1 Completed
NCT05201001 2023-09-11
APX005M
Nordic Society of Gynaecological Oncology - Clinical Trials Unit
Phase 2 Withdrawn
NCT03597282 2020-09-03
A Personal Cancer Vaccine (NEO-PV-01) and APX005M or Ipilimumab With Nivolumab in Patients With Advanced Melanoma
BioNTech SE
Phase 1 Terminated